Year None20232022202120202019201820172016 03-27-2023 Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference 03-13-2023 Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis 03-09-2023 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results 03-08-2023 Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors 03-01-2023 Pliant Therapeutics to Participate in Upcoming Investor Events 02-07-2023 Pliant Therapeutics to Participate in Upcoming Investor Events 02-02-2023 Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors 01-27-2023 Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares 01-25-2023 Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer 01-24-2023 Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering Pagination Current page 1 Page 2 Next page next › Last page last »